Memantina Flas Normon

Memantine Hydrochloride, the active ingredient in Memantina Flas Normon, is an NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults, where it helps to reduce excitotoxic neuronal damage associated with disease progression.

GNH USA supplies Memantina Flas Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks and quality assurance processes that meet European Union standards.

Memantina Flas Normon is an NMDA receptor antagonist used in the management of neurodegenerative dementia conditions. - Alzheimer’s disease (moderate to severe): improves cognition, global functioning and may slow disease progression in adult patients.

Memantina Flas Normon may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: temporary disorientation.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances. - Seizures: rare occurrence of convulsive episodes. - Severe hypertension: marked increase in blood pressure requiring medical attention.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for potential complications. - Renal function: evaluate creatinine clearance and adjust if necessary. - History of seizures: use with caution and monitor neurologic status. - Cardiovascular disease: observe blood pressure and heart rate. - Concomitant NMDA antagonists: avoid additive neuro‑psychiatric effects. - Hepatic impairment: consider dose modification. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Memantina Flas Normon can interact with other medicines that affect the central nervous system or NMDA pathways.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neuro‑psychiatric effects. - Ketamine: combined use can potentiate dissociative symptoms. - Other NMDA antagonists: risk of excessive CNS depression.

Moderate Interactions (Monitor Closely): - Diuretics: may raise plasma memantine concentrations. - Antihypertensives: potential for enhanced hypotensive response. - CNS depressants (e.g., benzodiazepines): may increase dizziness and sedation.